# ONCOLYTICS BIOTECH INC (ONCY) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_e042cad034d860083b7e · retrieved 2026-08-11T15:54:01.823Z

## Overview
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent designed to induce anti-cancer immune responses in multiple cancer types including pancreatic, breast, anal, and colorectal cancers.

Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing pelareorep, announced a proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada. The company cited its transition into a U.S.-focused clinical-stage oncology company, with predominantly U.S.-based operations, management, shareholder base, and capital markets activity. Effective January 1, 2026, Oncolytics became a domestic issuer under SEC rules and lost its "foreign private issuer" status, creating increased regulatory complexity. The proposed domestication is intended to simplify the regulatory structure, improve operational efficiency, and enhance access to U.S. capital markets. Shareholders of record as of December 9, 2025, will vote on the domestication at a special meeting scheduled for January 15, 2026.

## Key dates
- Announced 2026-01-09 · Record 2025-12-09 · Vote 2026-01-15

## Timeline
- 2026-01-09 · 425 (0001104659-26-002348): 425 - ONCOLYTICS BIOTECH INC — *Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent designed to induce anti-cancer immune responses in multiple cancer types including pancreatic, breast, anal, and colorectal cancers.* Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing pelareorep, announced a proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada. The company cited its transition into a U.S.-focused clinical-stage oncology company, with predominantly U.S.-based operations, management, shareholder base, and capital markets activity. Effective January 1, 2026, Oncolytics became a domestic issuer under SEC rules and lost its "foreign private issuer" status, creating increased regulatory complexity. The proposed domestication is intended to simplify the regulatory structure, improve operational efficiency, and enhance access to U.S. capital markets. Shareholders of record as of December 9, 2025, will vote on the domestication at a special meeting scheduled for January 15, 2026.
  https://www.sec.gov/Archives/edgar/data/1129928/0001104659-26-002348.txt

## Citations
- 0001104659-26-002348 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926002348